In broad terms, the company plans to sell cell types developed from the stem cells to drug companies for use in laboratory testing. Geron will also research a number of transplant applications. Such action in reminiscent of the action generated by the media reports in the summer about EntreMed's cancer products Endostatin and Angiostatin based on studies with mice. That piece of news gave a huge boost to EntreMed's trading action. So while there is cause for concern in this sector, there is still much to cheer.
More technologies are in the late stages than ever before.
Some 53 companies have products in late stage development, and a full 17 drugs are now awaiting final FDA approval. This means an abundance of news is ahead. All might not be good but our glass is still half full. Copyright 1997 - 2001 Core Communications Group, Inc.